Puma Biotechnology | PBYI - Interest Expense On Debt


Puma Biotechnology reported $3.37M in Interest Expense on Debt for its fiscal quarter ending in June of 2024.





Interest Expense On Debt Change Date
Agios Pharmaceuticals USD 1.11B 76.57M Jun/2026
Alnylam Pharmaceuticals USD 82.05M 12.76M Jun/2026
Amgen USD 95.64B 94.98B Jun/2026
Biogen USD 72.6M 12.6M Jun/2025
BioMarin Pharmaceutical USD 63.29M 48.34M Jun/2026
Daiichi Sankyo JPY 3.57B 1.4B Mar/2026
Exelixis USD 23.4M 3.9M Sep/2023
Gilead Sciences USD 247M 7M Jun/2026
Glaxosmithkline GBP 192.73M 14.79M Mar/2026
Incyte USD 582K 13K Jun/2026
MacroGenics USD 4.89M 1.55M Mar/2026
Moderna USD 10.96B 527M Jun/2026
Novartis USD 462M 119M Jun/2026
Pfizer USD 667M 4M Jun/2026
PTC Therapeutics USD 3.25B 381.37M Jun/2026
Puma Biotechnology USD 3.37M 11K Jun/2024
Regeneron Pharmaceuticals USD 11M 1.9M Jun/2026
Roche Holding CHF 304M 7.5M Jun/2025
Sangamo BioSciences 97.56M 11.39M Jun/2025
Sarepta Therapeutics USD 21.51M 205K Jun/2026
Takeda JPY 63.85B 20.2B Jun/2026
TG Therapeutics USD 16.57M 8.91M Jun/2026
Ultragenyx Pharmaceutical USD 22M 1000K Jun/2026
Vanda Pharmaceuticals -1.37B 1.97B Dec/2025
Vertex Pharmaceuticals USD 3.3M 0 Dec/2025